Loading...

Hideho Okada, MD, PhD

Title(s)Professor, Neurological Surgery
SchoolSchool of Medicine
Address1450 3rd Street
San Francisco CA 94158
Phone415-476-1637
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Nagoya University M.D.1991School of Medicine
    Nagoya University Ph.D.1996School of Medicine
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    Uehara Memorial Foundation 1996  - 1997Postdoctoral Scholarship
    Doris Duke Charitable Foundation 2001  - 2006Clinical Scientist Development Award
    James S. McDonnell’s Foundation2003  - 200721st Century Scientist Award
    Journal of Translational Medicine2006  - 2007Excellence in Translational Medicine Award
    University of Pittsburgh 2008Innovator Award
    University of Pittsburgh2009Faculty Honoree at the Annual Convocation
    American Society for Clinical Investigation (ASCI)2010Selected to be a Member
    Society for Immunotherapy for Cancer 2010Team Science Recognition Award
    University of Pittsburgh2011Faculty Honoree at the Annual Convocation
    University of Pittsburgh 2012Innovator Award
    University of Pittsburgh2013Faculty Honoree at the Annual Convocation
    University of Pittsburgh2014Faculty Honoree at the Annual Convocation

    Collapse Overview 
    Collapse Overview
    Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors. Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr. Okada's success in navigating the detailed regulatory processes that such trials require demonstrates his attention to detail and breadth of knowledge from basic science to clinical care. Dr. Okada's lab work was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes for gliomas. Dr. Okada's seminal discovery of CTL epitopes in glioma-associated antigens and the work on the mechanisms underlying the adjuvant effects of poly-ICLC enabled him to launch novel glioma vaccine trials in combination with poly-ICLC as an adjuvant. These efforts have also been supported by his mechanistic studies delineating the role of an integrin receptor very late activation antigen (VLA)-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has held 4 Investigational New Drug approvals for his own vaccine trials. Since 2004 to 2014, Dr. Okada served as a Co-Leader of the Brain Tumor Program within the University of Pittsburgh Cancer Institute and has worked to expand the program by developing strong interdisciplinary and translational research activities among program members. In 2010, Dr. Okada was selected to be a member of the American Society for Clinical Investigation, which is an honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice.

    Collapse Research 
    Collapse Research Activities and Funding
    Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade glioma
    NIH/NCI R21CA233856Feb 14, 2019 - Jan 31, 2021
    Role: Principal Investigator
    Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression
    NIH/NCI R01CA222965Jul 1, 2018 - Jun 30, 2023
    Role: Principal Investigator
    Preclinical development of breakthrough immunotherapy for brain tumors
    NIH/NINDS R35NS105068Dec 15, 2017 - Nov 30, 2025
    Role: Principal Investigator
    Novel K27M Mutation-derived Neoantigen for T Cell Therapy in Gliomas
    NIH/NINDS R01NS096954May 15, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Antigens for Molecularly Targeted Vaccines for Progressive Glioma
    NIH/NINDS R21NS093654Jul 1, 2015 - Jun 30, 2017
    Role: Principal Investigator
    Phase I Vaccine Study using Brain Tumor Initiating Cells in WHO Grade II Gliomas
    NIH/NCI R21CA177787Sep 25, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cells
    NIH/NINDS R21NS083171Sep 15, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Peptide-Based Vaccine Therapy for Childhood Malignant Gliomas
    NIH/NCI R21CA149872Mar 1, 2010 - Feb 28, 2013
    Role: Co-Principal Investigator
    A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma
    NIH/NCI R21CA133859Jul 1, 2009 - Jun 30, 2012
    Role: Principal Investigator
    Directing Tumor-specific T cells to Tumors
    NIH P01CA132714Apr 27, 2009 - Mar 31, 2014
    Role: Co-Investigator
    Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas
    NIH/NCI R21CA117152Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells
    NIH/NINDS R01NS055140Apr 1, 2006 - Jun 30, 2010
    Role: Principal Investigator
    Cytokine Gene Therapy of Cancer - Preclinical Studies
    NIH P01CA100327May 23, 2005 - Mar 31, 2011
    Role: Co-Investigator
    Novel Strategies for Brain Tumor Therapy
    NIH P01NS040923Dec 1, 2000 - Feb 28, 2014
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000056Dec 1, 1978 - Sep 29, 2006
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. Jpn J Clin Oncol. 2020 Sep 28. Nejo T, Mende A, Okada H. PMID: 32984905.
      View in: PubMed   Mentions:    Fields:    
    2. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020 Aug 20. Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. PMID: 32817593.
      View in: PubMed   Mentions:    Fields:    
    3. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer. 2020 Aug; 8(2). Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. PMID: 32843491.
      View in: PubMed   Mentions:    Fields:    
    4. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. J Neurooncol. 2020 Apr; 147(2):281-295. Kwok D, Okada H. PMID: 32185647.
      View in: PubMed   Mentions:    Fields:    
    5. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neurooncol Pract. 2020 Oct; 7(5):465-476. Montoya ML, Kasahara N, Okada H. PMID: 33014387.
      View in: PubMed   Mentions:
    6. Tumor antigens in glioma. Semin Immunol. 2020 02; 47:101385. Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. PMID: 32037183.
      View in: PubMed   Mentions:    Fields:    
    7. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020 Jan 27; 11(1):524. Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M. PMID: 31988324.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    8. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). J Immunother Cancer. 2019 11 29; 7(1):332. Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. PMID: 31783779.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    9. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. J Neurooncol. 2020 Jan; 146(1):71-78. Alcaide-Leon P, Luks TL, Lafontaine M, Lupo JM, Okada H, Clarke JL, Villanueva-Meyer JE. PMID: 31728884.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection. Magn Reson Med. 2020 03; 83(3):974-987. Hingorani DV, Chapelin F, Stares E, Adams SR, Okada H, Ahrens ET. PMID: 31631402.
      View in: PubMed   Mentions:    Fields:    
    11. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics. 2019 06; 18(6):1255-1268. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 31154438.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol Cell Proteomics. 2019 Jun; 18(6):1270. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 31154440.
      View in: PubMed   Mentions:    Fields:    
    13. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019 02 27; 7(1):58. Pinton L, Masetto E, Vettore M, Solito S, Magri S, D'Andolfi M, Del Bianco P, Lollo G, Benoit JP, Okada H, Diaz A, Della Puppa A, Mandruzzato S. PMID: 30813960.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    14. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019 02; 566(7745):E13. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. PMID: 30733620.
      View in: PubMed   Mentions: 1     Fields:    
    15. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Front Immunol. 2018; 9:3062. Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. PMID: 30740109.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    16. Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurg. 2019 Jan 21. Young JS, Dayani F, Morshed RA, Okada H, Aghi MK. PMID: 30677574.
      View in: PubMed   Mentions: 3     Fields:    
    17. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019 01; 565(7738):240-245. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. PMID: 30568303.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCellsCTClinical Trials
    18. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology. 2018; 7(12):e1501137. Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR. PMID: 30524896.
      View in: PubMed   Mentions:
    19. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics. 2018 11; 17(11):2132-2145. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 30072578.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    20. Immunotherapy of Primary Brain Tumors: Facts and Hopes. Clin Cancer Res. 2018 11 01; 24(21):5198-5205. Buerki RA, Chheda ZS, Okada H. PMID: 29871908.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    21. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight. 2018 04 05; 3(7). Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G. PMID: 29618666.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    22. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017 Dec 20; 18(1):234. Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A. PMID: 29262845.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    23. Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Sci Rep. 2017 12 18; 7(1):17748. Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET. PMID: 29255242.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    24. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018 01 02; 215(1):141-157. Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H. PMID: 29203539.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    25. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology. 2018; 7(2):e1391972. Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY. PMID: 29308320.
      View in: PubMed   Mentions:
    26. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 07 19; 9(399). O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. PMID: 28724573.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCTClinical Trials
    27. Is the immune response a friend or foe for viral therapy of glioma? Neuro Oncol. 2017 07 01; 19(7):882-883. Okada H, Thorne SH. PMID: 28874006.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017 Apr 03; 127(4):1425-1437. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H. PMID: 28319047.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    29. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017 06 29; 36(26):3749-3759. Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. PMID: 28218903.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    30. Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am. 2017 Feb; 27(1):155-166. Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A. PMID: 27889021.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    31. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016 12; 130(3):517-527. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. PMID: 27624914.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 12; 130(3):543-552. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. PMID: 27624915.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    33. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 08 10; 6:31397. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. PMID: 27507680.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    34. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016 10; 16(10):1265-75. Lin Y, Okada H. PMID: 27434205.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    35. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016 10; 18(10):1402-12. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N. PMID: 27116977.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    36. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016 08; 18(8):1157-68. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. PMID: 26984745.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    37. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. PMID: 27471611.
      View in: PubMed   Mentions:
    38. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015 Dec; 125(3):631-5. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. PMID: 26530260.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. PMID: 26545842.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    40. Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii3-vii8. Dunn GP, Okada H. PMID: 26516224.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    41. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology. 2015 Nov; 4(11):e1047581. Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H. PMID: 26451324.
      View in: PubMed   Mentions:
    42. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015 Jun; 4(6):e1008347. Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL. PMID: 26155415.
      View in: PubMed   Mentions:
    43. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46. Reardon DA, Okada H. PMID: 25707876.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. PMID: 25696001.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimals
    45. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun. 2015 Mar 13; 458(3):549-554. Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H. PMID: 25677619.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    46. Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology. 2015 Apr; 4(4):e999523. Ohkuri T, Ghosh A, Kosaka A, Sarkar SN, Okada H. PMID: 26137417.
      View in: PubMed   Mentions:
    47. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. PMID: 25537519.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansAnimals
    48. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014; 2(1):46. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. PMID: 25598973.
      View in: PubMed   Mentions: 16     Fields:    
    49. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015 Jan 15; 21(2):286-94. Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. PMID: 25424847.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    50. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014 Dec; 2(12):1199-208. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H. PMID: 25300859.
      View in: PubMed   Mentions: 49     Fields:    Translation:AnimalsCells
    51. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 01; 32(19):2050-8. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. PMID: 24888813.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    52. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother. 2014 Aug; 63(8):847-57. Kosaka A, Ohkuri T, Okada H. PMID: 24878890.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    53. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013; 1:21. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H. PMID: 24829757.
      View in: PubMed   Mentions: 25     Fields:    
    54. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013 Nov 01; 5(4):1379-412. Ahn BJ, Pollack IF, Okada H. PMID: 24202450.
      View in: PubMed   Mentions:
    55. Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother. 2013 Oct; 13(10):1089-98. Pollack IF, Jakacki RI, Butterfield LH, Okada H. PMID: 24117271.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-a. Cancer Res. 2013 Nov 01; 73(21):6413-23. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. PMID: 24030977.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    57. Peptide vaccine therapy for childhood gliomas. Neurosurgery. 2013 Aug; 60 Suppl 1:113-9. Pollack IF, Jakacki RI, Butterfield LH, Okada H. PMID: 23839362.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    58. In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging. PLoS One. 2013; 8(5):e59479. Zhong J, Sakaki M, Okada H, Ahrens ET. PMID: 23667419.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    59. Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci. 2013 May; 1284:17-23. Okada H, Scheurer ME, Sarkar SN, Bondy ML. PMID: 23651189.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    60. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol. 2013 Jul; 15(7):891-903. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. PMID: 23595625.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    61. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 2013 Apr 01; 19(7):1816-26. Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. PMID: 23401227.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    62. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol. 2013 Jan; 111(2):103-11. Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. PMID: 23179498.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    63. Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Adv Virol. 2012; 2012:815465. Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P. PMID: 22924042.
      View in: PubMed   Mentions:
    64. Differential activity of interferon-a8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. Oncoimmunology. 2012 Jul 01; 1(4):487-492. Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H. PMID: 22754767.
      View in: PubMed   Mentions:
    65. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. PMID: 22640522.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    66. Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol. 2012 Aug; 32(4):802-8. Okada H, Khoury SJ. PMID: 22454247.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    67. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor a2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy. 2012 Jul; 14(6):733-42. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T. PMID: 22424217.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    68. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012 Feb 15; 188(4):1782-8. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. PMID: 22246626.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    69. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest. 2012; 41(6-7):658-79. Kohanbash G, Okada H. PMID: 23017140.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    70. MicroRNAs and STAT interplay. Semin Cancer Biol. 2012 Feb; 22(1):70-5. Kohanbash G, Okada H. PMID: 22210182.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    71. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012 Jun; 61(6):789-801. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. PMID: 22065046.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    72. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 2011 Aug; 50(2-3):235-47. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. PMID: 21717071.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    73. Absence of Stat1 in donor CD4? T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 2011 Jul; 121(7):2554-69. Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY. PMID: 21670504.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    74. Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother. 2011 May; 11(5):619-22. Okada H, Pollack IF. PMID: 21539483.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    75. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011 Apr 01; 71(7):2664-74. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. PMID: 21324923.
      View in: PubMed   Mentions: 124     Fields:    Translation:AnimalsCells
    76. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 Jan 20; 29(3):330-6. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. PMID: 21149657.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansCellsCTClinical Trials
    77. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol. 2011 Aug; 104(1):83-92. Zhu X, Fujita M, Snyder LA, Okada H. PMID: 21116835.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    78. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother. 2010 Sep; 59(9):1401-9. Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H. PMID: 20549206.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCellsPHPublic Health
    79. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010 Jul 01; 16(13):3409-19. Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. PMID: 20472682.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    80. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One. 2010 May 05; 5(5):e10492. Steitz J, Barlow PG, Hossain J, Kim E, Okada K, Kenniston T, Rea S, Donis RO, Gambotto A. PMID: 20463955.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    81. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 2010 Jun; 22(3):173-82. Kalinski P, Okada H. PMID: 20409732.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    82. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med. 2010 Feb 18; 8:17. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H. PMID: 20167088.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    83. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010 Aug; 42(8):1256-61. Okada H, Kohanbash G, Lotze MT. PMID: 20144731.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    84. Balb/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP: a novel model for the study of tolerance mechanisms and vaccine efficacy. Mol Immunol. 2010 Feb; 47(5):1149-53. Steitz J, Soloff AC, Barratt-Boyes SM, Alber SM, Watkins SC, Okada H, Gambotto A. PMID: 20022379.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    85. Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S75-81. Gardner SL, Ahmed N, Okada H. PMID: 19896544.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    86. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009 Nov 01; 15(21):6551-9. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. PMID: 19861464.
      View in: PubMed   Mentions: 46     Fields:    Translation:AnimalsCells
    87. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother. 2009 Oct; 32(8):793-802. Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. PMID: 19752754.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    88. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci. 2009 Sep; 1174:18-23. Okada H. PMID: 19769732.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    89. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10746-51. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H. PMID: 19520829.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    90. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther. 2009 Dec; 16(12):883-91. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ. PMID: 19444303.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    91. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res. 2009 Feb 15; 69(4):1587-95. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H. PMID: 19190335.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    92. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009; 29(1):1-42. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M. PMID: 19348609.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    93. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol. 2008 Oct; 38(10):2865-73. Sasaki K, Pardee AD, Okada H, Storkus WJ. PMID: 18958887.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    94. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol. 2008 Jul 01; 181(1):104-8. Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. PMID: 18566374.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    95. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol. 2008 Jul; 88(3):245-50. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. PMID: 18324354.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    96. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008 Feb 15; 180(4):2089-98. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H. PMID: 18250414.
      View in: PubMed   Mentions: 48     Fields:    Translation:AnimalsCells
    97. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007 Dec 19; 5:67. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC, Pollack IF. PMID: 18093335.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCellsCTClinical Trials
    98. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med. 2007 Dec 19; 5:68. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H. PMID: 18093336.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    99. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8. Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. PMID: 17942935.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    100. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007 Jul 01; 67(13):6451-8. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. PMID: 17616706.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    101. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol. 2007 Mar 15; 178(6):3400-8. Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. PMID: 17339434.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    102. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12; 5:10. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. PMID: 17295916.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    103. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):566-575. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR. PMID: 17255279.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    104. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol. 2007; 377:203-22. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J. PMID: 17634619.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    105. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006 Jun 01; 66(11):5883-91. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H. PMID: 16740728.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    106. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006 Apr 15; 66(8):4478-87. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. PMID: 16618775.
      View in: PubMed   Mentions: 44     Fields:    Translation:AnimalsCells
    107. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther. 2005 Sep; 12(9):757-68. Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H. PMID: 15832173.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    108. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005 Aug 15; 175(4):2730-40. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. PMID: 16081851.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    109. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005 Aug; 7(8):717-22. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. PMID: 16207473.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    110. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol. 2005 Jun 01; 174(11):7194-201. Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. PMID: 15905564.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    111. [Immunotherapy for brain tumor: don't get "Lost in Translation"]. No Shinkei Geka. 2005 May; 33(5):433-42. Okada H. PMID: 15912763.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    112. The characterization of tumor apoptosis after experimental radiosurgery. Stereotact Funct Neurosurg. 2005; 83(1):17-24. Witham TF, Okada H, Fellows W, Hamilton RL, Flickinger JC, Chambers WH, Pollack IF, Watkins SC, Kondziolka D. PMID: 15775705.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    113. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004 Nov 24; 2(1):40. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. PMID: 15563374.
      View in: PubMed   Mentions: 29     Fields:    
    114. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther. 2004 Nov; 11(21):1551-8. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H. PMID: 15343358.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    115. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther. 2004 Oct; 4(10):1609-20. Okada H, Pollack IF. PMID: 15461572.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    116. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. 2004 Aug 15; 64(16):5830-8. Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF. PMID: 15313927.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    117. Biologic therapy for brain cancers--based on cellular and immunobiology. Yonsei Med J. 2004 Jun 30; 45 Suppl:68-70. Okada H. PMID: 15250054.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003 Oct 01; 63(19):6378-86. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ. PMID: 14559827.
      View in: PubMed   Mentions: 35     Fields:    Translation:AnimalsCells
    119. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol. 2003 Aug-Sep; 64(1-2):13-20. Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC, Pollack IF. PMID: 12952282.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    120. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol. 2003 Aug-Sep; 64(1-2):63-9. Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH. PMID: 12952287.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    121. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther. 2003 Jul; 10(7):549-58. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. PMID: 12833135.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    122. Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther. 2002 Dec; 2(4):437-50. Okada H, Kuwashima N. PMID: 12477255.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    123. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002 Sep; 8(9):2851-5. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. PMID: 12231526.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    124. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery. 2002 Jun; 50(6):1327-34; discussion 1334-5. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. PMID: 12015852.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCellsPHPublic Health
    125. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 2002 May 01; 62(9):2583-91. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH. PMID: 11980653.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    126. Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors. J Neurosurg. 2001 Dec; 95(6):984-9. Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF. PMID: 11765844.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    127. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001 Aug; 8(15):1157-66. Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH. PMID: 11509946.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    128. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001 Mar 20; 12(5):575-95. Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D. PMID: 11268289.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    129. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res. 2001 Mar 15; 61(6):2625-31. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH. PMID: 11289140.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    130. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Pediatr Neurol. 2000 Jun; 7(2):131-43. Pollack IF, Okada H, Chambers WH. PMID: 10914414.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    131. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. 2000 May 01; 60(9):2449-57. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH. PMID: 10811123.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    132. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. 2000 Mar; 7(3):486-94. Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT. PMID: 10766355.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    133. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther. 2000 Mar 01; 11(4):637-53. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. PMID: 10724042.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    134. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S61-6. Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robbins P. PMID: 10685662.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    135. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999 Feb; 6(2):219-26. Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME. PMID: 10435106.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    136. [Neurosurgery and molecular biology: (series 10) gene therapy and biological therapy for brain tumors]. No Shinkei Geka. 1999 Jan; 27(1):9-17. Okada H. PMID: 10024979.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    137. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998 Oct 05; 78(2):196-201. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME. PMID: 9754652.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    Hideho's Networks
    Concepts (470)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (46)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑